NLS Agreement

Zealand Pharma has entered into a royalty purchase and sale agreement with Royalty Pharma in exchange for Zealand Pharma’s economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.

Swedish Orphan Biovitrum and Innate Pharma have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL).

AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.

Prolight Diagnostics has announces the successful completion of a 260-patient feasibility study and the subsequent signing of a development agreement with BRAINBox Solutions.

AlzeCure Pharma has entered into an out-licensing and collaboration agreement with QuantumCell, a Danish tech-enabled biotech company, regarding the global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856.

The company has entered into the agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration.